Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Return on Capital Employed (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Return on Capital Employed for 2 consecutive years, with 0.48% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 85.0% to 0.48% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.48% through Dec 2025, up 85.0% year-over-year, with the annual reading at 0.74% for FY2025, N/A changed from the prior year.
  • Return on Capital Employed hit 0.48% in Q4 2025 for Xilio Therapeutics, up from 0.57% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.48% in Q4 2025 to a low of 1.43% in Q1 2025.